News

July 20, 2026

HistoSonics Opens Expanded Histotripsy Training Center in Hong Kong

HistoSonics announced the opening of its expanded Histotripsy Training Center in Hong Kong, reinforcing the city's position as a leading […]
July 13, 2026

HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization

HistoSonics announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the […]
June 22, 2026

HistoSonics Announces Financing with Participation from Yosemite Among Other Strategic Investors

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the closing of a new […]
May 18, 2026

HistoSonics Receives Landmark TFDA Approval in Taiwan, Accelerating Global Expansion

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has received approval from […]
May 11, 2026

HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has submitted a De […]
March 30, 2026

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the […]
1 2 3 9

Last updated on July 20, 2026

Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

The is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the for the treatment of cancer, any cancer outcomes (such as local tumor progression, 5-year survival or overall survival), or any other specific disease. The System should only be used by persons who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.

Footer last updated on July 21, 2026
X New Twitter Logo
© 2019-2026 HistoSonics®. All rights reserved.
HistoSonics
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.